RxDoctor Payments Data

Anuragh Trikha, MD

Pain Medicine · Baltimore, MDNPI 1265920375

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,928 of the $9,127 with a category attached, or 65.0%. 23 manufacturers reported payments, led by Medtronic at 30.9% of the total.

$9,127in general payments, 2019–2025

Across 224 payments — averaging $40.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$2K
  • Collegium Pharmaceutical, Inc.$505
  • Nevro Corp.$496
  • Abbott$408
  • Saluda Medical Americas, Inc.$369
  • plus $2K from 17 others

What the payments were for

  • Travel & lodging$3,15935%
  • Food & beverage$5,92865%
  • Education$400%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,127 in reported general payments places this provider in the 75th percentile of 144 pain medicine providers in Maryland.

See all pain medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$154,187
Medicare patients
307
Services billed
2,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl22$19,089
ZtlidoLidocaine17$5,684
Lidocaine41$5,575
Oxycodone Hcl265$4,262
Gabapentin307$3,379
Diclofenac Sodium73$3,049
Celecoxib136$2,751
Pregabalin81$2,474
Buprenorphine12$2,471
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen93$2,343
Methocarbamol102$1,511
Naloxone Hcl17$1,280
Cyclobenzaprine Hcl96$1,002
Baclofen75$961
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen33$784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$505$19,08922 claims
Scilex Pharmaceuticals Inc.Ztlido$36$5,68417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 144 pain medicine providers in Maryland.

Other pain medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →